We produce institutional quality equity research on small/midcap healthcare and life sciences companies, making it available to all investors wherever they are based. Our goal is to bring exciting investment ideas to investors, and to assist companies in achieving their objectives.
11
Research Clients
170
Reports published
10k+
Readers in database
Multi-target #RareDisease deal b/w @TakedaPharma & @EvOx_Ltd covers development of up to 5 novel protein replacement & mRNA therapies using Evox’s proprietary #exosome technology. Total milestone potential of $882m, with $44m in near-term payments https://reut.rs/2UCOOM7
Sage advice and insights from @lifesciVC on Strategic Planning In Biotech During A Pandemic Crisis #COVID19
https://lifescivc.com/2020/03/strategic-planning-in-biotech-during-a-pandemic-crisis/
A helpful tracker of clinical trials disrupted by the #COVID19 pandemic via @BioPharmaDive @benthefidler
https://www.biopharmadive.com/news/coronavirus-clinical-trial-disruption-biotech-pharma/574609/
Development & commercialisation partnership b/w @MaxCyte_info & leading #AdvancedCellTherapy company @AllogeneTx enables advancement of $ALLO ’s off-the-shelf AlloCAR T #Cancer therapies $MXCT https://otp.tools.investis.com/clients/uk/maxcyte1/rns/regulatory-story.aspx?cid=1311&newsid=1381398
Potential for #CERAMENT G US approval for #osteomyelitis in late-2020 (following a planned April FDA 'de novo' filing) is a new addition to @BONESUPPORT_AB's catalyst calendar #BONEX
A very thought-provoking graphic from @VisualCap #COVID19 #coronavirus
Visualizing the History of Pandemics https://www.visualcapitalist.com/history-of-pandemics-deadliest/
Please sign up here to be added to our distribution database
